Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relypsa Inc.

This article was originally published in Start Up

Executive Summary

When Amgen bought Ilypsa last summer, it kept one of its non-absorbed polymer drug candidates for itself, leaving Ilypsa's other candidates in limbo. Key Ilypsa employees and investors wanted to carry out those programs, and with Amgen's blessing, they moved swiftly to form Relypsa Inc., which retains rights to Ilypsa's remaining pipeline and drug discovery platform. Relypsa management, all from Ilypsa, intends to continue Ilypsa's fast pace of pipeline development, with a NCE planned for entry into the clinic every year for the next three years.

You may also be interested in...



Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007

We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2007

We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.

Start-Up Previews

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel